Nasdaq
華爾街日報Reported Earlier, Ascentage Pharma Highlights Olverembatinib 4-Year Follow-Up At ASH 2025, Showing EFS Advantage Versus Best Available Therapy In CML-CP
Benzinga·12/09/2025 07:59:59
語音播報
- Dramatically improved disease control with 21.2 months vs. 2.9 months median event-free survival (EFS)
- Favorable safety profile with 7% vascular occlusion rate
- Broad patient benefit with proven effectiveness even in patients without T315I mutation (11.9 vs. 3.1 months event-free survival)